1. Home
  2. VZLA vs TNDM Comparison

VZLA vs TNDM Comparison

Compare VZLA & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VZLA

Vizsla Silver Corp.

HOLD

Current Price

$6.12

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$20.18

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VZLA
TNDM
Founded
2017
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VZLA
TNDM
Price
$6.12
$20.18
Analyst Decision
Strong Buy
Buy
Analyst Count
2
17
Target Price
$7.00
$24.06
AVG Volume (30 Days)
7.0M
1.2M
Earning Date
12-12-2025
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,007,001,000.00
Revenue This Year
N/A
$8.59
Revenue Next Year
N/A
$10.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
17.87
52 Week Low
$1.69
$9.98
52 Week High
$6.16
$37.93

Technical Indicators

Market Signals
Indicator
VZLA
TNDM
Relative Strength Index (RSI) 66.02 40.47
Support Level $5.71 $20.21
Resistance Level $6.08 $23.95
Average True Range (ATR) 0.26 1.11
MACD 0.01 -0.39
Stochastic Oscillator 98.11 0.03

Price Performance

Historical Comparison
VZLA
TNDM

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: